Generex Biotechnology Corporation Comments On Recent Trading Activity Related to Discontinuation of Inhaled Insulin Products

WORCESTER, Mass., March 10, 2008 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, commented on trading activity in its stock. The Company believes that the decline in its common stock today is related to the decisions of Eli Lilly and Company as well as Pfizer and Novo Nordisk to discontinue the development of their inhaled insulin products. Generex believes that those decisions enhance its competitive position in the marketplace, as it removes potentially competitive products. Unlike safety concerns related to those products, Generex's proprietary platform technology delivers insulin into the human body through the oral cavity, with no deposit in the lungs. In clinical tests, the drug has always demonstrated an excellent safety profile. Generex recently commenced a Phase III study of its flagship product, Generex Oral-lyn(tm), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes and which was approved for sale in India in October 2007.